- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01341392
Drug-drug Interaction Study(CKD-501, Amlodipine)
August 11, 2011 updated by: Chong Kun Dang Pharmaceutical
A Randomized, Open-label, Multiple Dose, Three-treatment, Three-period, Six-sequence Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between CKD-501 and Amlodipine After Oral Administration in Healthy Male Volunteers
The purpose of this study is to assess the pharmacokinetic drug interaction between CKD-501 and amlodipine after oral administration in healthy male volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Volunteers doses three times over the period of CKD-501 0.5mg or Amlodipine 10mg alone/co-administrate, repeated doses are 10 days.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Severance Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Between 20 aged and 45 years old in healthy males
- Body weight ≥ 55kg and 18.5 ≤ IBW < 25
- Agreement with written informed consent
Exclusion Criteria:
- Subject has a history affects the ADME of drug
- Hypersensitivity reactions to drugs or clinically significant hypersensitivity reactions in the history of party
- Inadequate subject by medical examination(medical history, physical examination, ECG, laboratory test)
- AST,ALT > UNL * 1.25 or Total bilirubin > UNL * 1.5
- Estimated GFR(MDRD) < 80
- SBP >150 mmHg, SBP < 100 mmHg or DBP > 100 mmHg, DBP < 60 mmHg or Pulse > 100 per/min, Pulse < 50 per/min
- Substance abuse, or a history of drug abuse showed a positive for the party
- Continued to be taking caffeine (caffeine > 5 cup/day), drinking (alcohol > 210 g/week) or cannot stop drinking or severe heavy smoker(cigarette > 10 cigarettes per day)during clinical trials
- Medication with drug-mediated induction/inhibition metabolic enzyme within 30 days or with may affect the clinical trial
- Medication within 2 weeks in the first professional medical, medicine, OTC, vitamins taking
- Subject takes grapefruit within 1 month
- Previously participated in other trial within 60 days
- Previously donate whole blood within 60 days or component blood within 30 days
- An impossible one who participates in clinical trial by investigator's decision including laboratory test result
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CKD-501 0.5mg
Subjects received CKD-501 0.5mg once daily for 10 days.
Subjects received amlodipine 10mg once daily for 10 days.
Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
|
Subjects received CKD-501 0.5mg once daily for 10 days.
Subjects received amlodipine 10mg once daily for 10 days.
Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
Other Names:
|
Experimental: CKD-501 Amlodipine
Subjects received CKD-501 0.5mg once daily for 10 days.
Subjects received amlodipine 10mg once daily for 10 days.
Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
|
Subjects received CKD-501 0.5mg once daily for 10 days.
Subjects received amlodipine 10mg once daily for 10 days.
Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
|
Experimental: Amlodipine 10mg
Subjects received CKD-501 0.5mg once daily for 10 days.
Subjects received amlodipine 10mg once daily for 10 days.
Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
|
Subjects received CKD-501 0.5mg once daily for 10 days.
Subjects received amlodipine 10mg once daily for 10 days.
Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CKD-501 AUC
Time Frame: Pre dose(D8-9, D29-30, D50-51), 0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24hr
|
Pre dose(D8-9, D29-30, D50-51), 0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24hr
|
Amlodipine AUC
Time Frame: Pre dose(D8-9, D29-30, D50-51), 0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 48, 72hr
|
Pre dose(D8-9, D29-30, D50-51), 0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 48, 72hr
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CKD-5011 Tmax
Time Frame: Pre dose(D8-9, D29-30, D50-51), 0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24hr
|
Pre dose(D8-9, D29-30, D50-51), 0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24hr
|
Amlodipine Tmax
Time Frame: Pre dose(D8-9, D29-30, D50-51), 0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 48, 72hr
|
Pre dose(D8-9, D29-30, D50-51), 0, 0.33, 0.67, 1, 1.33, 1.67, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 48, 72hr
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
April 22, 2011
First Submitted That Met QC Criteria
April 22, 2011
First Posted (Estimate)
April 25, 2011
Study Record Updates
Last Update Posted (Estimate)
August 15, 2011
Last Update Submitted That Met QC Criteria
August 11, 2011
Last Verified
August 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Amlodipine
Other Study ID Numbers
- 19HPS11H
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on CKD-501
-
Chong Kun Dang PharmaceuticalCompletedType 2 Diabetes MellitusKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type 2Korea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType 2 DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType 2 DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType2 Diabetes MellitusKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHealthy | Renal ImpairmentKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType 2 DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknownType2 Diabetes MellitusKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type IIKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedLiver DysfunctionKorea, Republic of